A rise in regulatory policies in China favoring domestic products puts a premium on companies achieving some level of localization in the country. Establishing a China-based manufacturing footprint is crucial to this end, but the exact definition of “local” is evolving. Context and considerations from Grace Wang and Helen Chen at L.E.K. Consulting.
Welcome to MyStrategist, the digital home for Market Pathways.
Market Pathways covers the people, challenges, and opportunities impacting the global medtech regulatory, reimbursement, and policy communities. We invite you to explore our coverage. Think Strategically.
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market PathwaysStart Trial
A sortable and searchable running inventory of global medtech regulatory and policy official documents, including rules, guidance documents, memos, white papers, and more from national authorities, non-governmental groups, and global organizations.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.Learn More
Our infographic sums up the year in global policymaking: FDA approvals, CMS output, mapping notified bodies, innovative payment schemes in Europe and more.